Exploration of the role of drug resistance-associated anoikis-related genes in HER2-Negative breast cancer through bioinformatics analysis

IF 2.3 Q3 BIOCHEMISTRY & MOLECULAR BIOLOGY

Biochemistry and Biophysics Reports Pub Date : 2025-02-21 DOI:10.1016/j.bbrep.2025.101947

Yuanzhao Wu, Cong Chen, Zao Jin, Kesi Zheng

{"title":"Exploration of the role of drug resistance-associated anoikis-related genes in HER2-Negative breast cancer through bioinformatics analysis","authors":"Yuanzhao Wu, Cong Chen, Zao Jin, Kesi Zheng","doi":"10.1016/j.bbrep.2025.101947","DOIUrl":null,"url":null,"abstract":"<div><h3>Aims</h3><div>To explore the potential functions and impacts of anoikis-related genes (ARGs) in breast cancer chemotherapy and to construct a prognosis model for HER2-negative breast cancer (HNBC) based on drug resistance-related ARGs.</div></div><div><h3>Background</h3><div>Breast cancer remains a leading cause of cancer-related mortality, with HER2-negative subtypes exhibiting high rates of metastasis and recurrence. Standard treatments for HNBC include taxane- and anthracycline-based chemotherapies, which aim to mitigate recurrence and metastasis. Anoikis, a specialized form of programmed cell death, plays a pivotal role in maintaining tissue homeostasis by eliminating detached cells. Cancer cells often develop resistance to anoikis, enabling survival in adverse conditions and promoting tumor progression.</div></div><div><h3>Objective</h3><div>To investigate the intersection of breast cancer drug resistance-related genes and anoikis-related genes (ARGs) and to assess their potential as biomarkers for HNBC. The study also aims to analyze differences in immune microenvironment and drug sensitivity among different prognosis score groups.</div></div><div><h3>Method</h3><div>A bioinformatics approach was employed to identify the intersection of breast cancer drug resistance-related genes and ARGs. A prognosis model for HNBC was developed based on these identified drug resistance-related ARGs. The study further examined differences in the immune microenvironment and drug sensitivity among different prognosis score groups.</div></div><div><h3>Result</h3><div>A prognosis model for HNBC was successfully constructed based on drug resistance-related ARGs. The study identified significant differences in immune microenvironment and drug sensitivity across different prognosis score groups.</div></div><div><h3>Conclusion</h3><div>The findings suggest that ARGs could be key in tailoring more effective therapeutic approaches for patients with HER2-negative breast cancer.</div></div>","PeriodicalId":8771,"journal":{"name":"Biochemistry and Biophysics Reports","volume":"41 ","pages":"Article 101947"},"PeriodicalIF":2.3000,"publicationDate":"2025-02-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biochemistry and Biophysics Reports","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2405580825000342","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Aims

To explore the potential functions and impacts of anoikis-related genes (ARGs) in breast cancer chemotherapy and to construct a prognosis model for HER2-negative breast cancer (HNBC) based on drug resistance-related ARGs.

Background

Breast cancer remains a leading cause of cancer-related mortality, with HER2-negative subtypes exhibiting high rates of metastasis and recurrence. Standard treatments for HNBC include taxane- and anthracycline-based chemotherapies, which aim to mitigate recurrence and metastasis. Anoikis, a specialized form of programmed cell death, plays a pivotal role in maintaining tissue homeostasis by eliminating detached cells. Cancer cells often develop resistance to anoikis, enabling survival in adverse conditions and promoting tumor progression.

Objective

To investigate the intersection of breast cancer drug resistance-related genes and anoikis-related genes (ARGs) and to assess their potential as biomarkers for HNBC. The study also aims to analyze differences in immune microenvironment and drug sensitivity among different prognosis score groups.

Method

A bioinformatics approach was employed to identify the intersection of breast cancer drug resistance-related genes and ARGs. A prognosis model for HNBC was developed based on these identified drug resistance-related ARGs. The study further examined differences in the immune microenvironment and drug sensitivity among different prognosis score groups.

Result

A prognosis model for HNBC was successfully constructed based on drug resistance-related ARGs. The study identified significant differences in immune microenvironment and drug sensitivity across different prognosis score groups.

Conclusion

The findings suggest that ARGs could be key in tailoring more effective therapeutic approaches for patients with HER2-negative breast cancer.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Biochemistry and Biophysics Reports Biochemistry, Genetics and Molecular Biology-Biophysics

CiteScore

4.60

自引率

0.00%

发文量

191

审稿时长

59 days

期刊介绍： Open access, online only, peer-reviewed international journal in the Life Sciences, established in 2014 Biochemistry and Biophysics Reports (BB Reports) publishes original research in all aspects of Biochemistry, Biophysics and related areas like Molecular and Cell Biology. BB Reports welcomes solid though more preliminary, descriptive and small scale results if they have the potential to stimulate and/or contribute to future research, leading to new insights or hypothesis. Primary criteria for acceptance is that the work is original, scientifically and technically sound and provides valuable knowledge to life sciences research. We strongly believe all results deserve to be published and documented for the advancement of science. BB Reports specifically appreciates receiving reports on: Negative results, Replication studies, Reanalysis of previous datasets.